Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.

Pectasides D, Dafni U, Aravantinos G, Timotheadou E, Skarlos DV, Pavlidis N, Gaglia A, Kalofonos HP, Fountzilas G.

Anticancer Res. 2007 Nov-Dec;27(6C):4411-7.

3.

Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group.

Clavel M, Bonneterre J, d'Allens H, Paillarse JM.

Eur J Cancer. 1995;31A(1):15-9.

PMID:
7695971
4.

A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group study.

Janinis J, Giannakakis T, Athanasiades A, Fountzilas G, Bafaloukos D, Kosmidis P, Nikolaides K, Pavlidis N, Skarlos D.

Tumori. 2000 Jan-Feb;86(1):37-41.

PMID:
10778764
5.

[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].

Hebbar M, Hecquet B, Vanlemmens L, Lecomte S, Pion JM, Adenis A, Bonneterre J.

Bull Cancer. 1995 Jan;82(1):67-9. French.

PMID:
7742620
6.

Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment.

LeBourgeois JP, McKenna CJ, Coster B, Feyer P, Franzén L, Goedhals L, Marzecki Z, Souhami L, Stewart A, Tønnessen F, Haigh C, Mitchell T, Wilkinson JR, Graham E.

Clin Oncol (R Coll Radiol). 1999;11(5):340-7.

PMID:
10591823
7.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
8.

Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.

Barrenetxea G, Schneider J, Centeno MM, Romero H, de la Rica M, Rodríguez-Escudero FJ.

Cancer Chemother Pharmacol. 1996;38(5):471-5.

PMID:
8765442
9.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
12.

[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].

Nukariya N, Niitani H, Taguchi T, Furue H, Ota K, Tsukagoshi S, Ariyoshi Y, Ikeda M, Akasaka Y, Ohta J, et al.

Gan To Kagaku Ryoho. 1992 Aug;19(9):1347-57. Japanese.

PMID:
1386976
13.

Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.

Marschner N.

Eur J Cancer. 1991;27 Suppl 1:S15-7; discussion S22. Review.

PMID:
1831629
14.

Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.

Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B.

Eur J Cancer. 1991;27(9):1137-40. Erratum in: Eur J Cancer 1991;27(12):1717.

PMID:
1835624
15.

Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.

Nicolaides C, Giannakakis T, Skarlos D, Athanassiadis A, Fountzilas G, Damigos D, Pavlidis N.

J Exp Clin Cancer Res. 1998 Mar;17(1):71-5.

PMID:
9646236
17.
18.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F.

J Clin Oncol. 2005 Apr 20;23(12):2822-30. Erratum in: J Clin Oncol. 2005 Aug 20;23(24):5851. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
15837996
19.

[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].

Ariyoshi Y, Nukariya N, Akasaka Y, Suminaga M, Ota J, Ikeda M, Taguchi T.

Gan To Kagaku Ryoho. 1997 Jun;24(8):995-1011. Japanese.

PMID:
9212810

Supplemental Content

Support Center